Department: Market Access

Director, Market Access

Summary:

The Director, Market Access will be responsible for implementation of market interventions, contributing to rapid introduction, and broad access to novel TB regimens in low- and middle-income countries especially those with high incidence of tuberculosis.

The position is broad in scope, with interventions at global, regional and country level, in collaboration with technical, global health and commercial partners, and will play a pivotal role in creating global access to TB Alliance developed regimens.

The Market Access function at the TB Alliance includes all elements on the value chain including supplier relationship management, pricing strategy, forecasting, market understanding, resource mobilization, support for policy change, regulatory issues, diagnostics as well as technical adoption-related issues. 

The opening is happening at an exciting time for new TB regimens. Regulatory approval for a novel, short, all-oral regimen for XDR-TB has recently been obtained, and work is ongoing to support planning for a forthcoming short regimen for both DS and MDR-TB.

Position description:

  • Coordinate with local agencies, technical partners, commercial partners and global health stakeholders for design and implementation of in-country and regional access initiatives in select high priority countries
  • Identify novel opportunities to advance access in select high priority countries and help develop collaborations to actualize the same, including access and uptake financing
  • Foster and manage relationships in select high priority countries to support objectives of the Alliance
  • Help design market research and other exercises to generate evidence to support adoption and uptake of novel TB medicines
  • Responsible for compliance with applicable GxP regulations in performing the functions of the job, including attendance at annual GxP or other applicable regulatory trainings provided by TB Alliance.

Ideal candidates will have:

  • 10+ years’ professional experience in product or service development and launch of health products in emerging markets and developing countries.
  • Experience and deep understanding of current TB landscape, including bottlenecks and solutions to implementation of TB treatments in high burden countries, highly preferred.
  • Working knowledge of public health systems and private health care treatment in countries with high incidence of tuberculosis
  • Networks and strong relationships in high burden countries, at least in one key region
  • Understanding of concepts of market research applied to design solutions to public health issues
  • Relevant educational background; MPH or MBA or other relevant advanced degree
  • Ability to absorb and synthesize a broad range of information, especially clinical and scientific information
  • Ability to think strategically, handle ambiguity, problem solve, collaborate with a small team, and work across several projects concurrently
  • Excellent project management, communication and analytical skills
  • Commitment to global health and neglected diseases, specifically TB.

Location:

New York, NY

Organizational Information:

TB Alliance is a not-for-profit organization dedicated to the discovery and development of better, faster, affordable tuberculosis drugs that are available to those who need them.Through innovative science and with partners around the globe, we lead a global effort to ensure development of and equitable access to faster, better tuberculosis cures that will advance global health and prosperity.

With an annual operating budget of approximately $60 million, the TB Alliance leads the advancement of the most comprehensive R&D portfolio of TB drug candidates in history. Additionally, the TB Alliance drives efforts to ensure regulatory approval, country adoption of new regimens, and widespread availability of new drug regimens to patients. For more information, please access the website: www.tballiance.org.

Our Pipeline

TB Alliance manages the largest pipeline of new TB drugs in history.

View the portfolio